TYSABRI — Total Revenue
Biogen TYSABRI — Total Revenue increased by 11.1% to $441.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $381.50M to $441.50M. Over 4 years (FY 2021 to FY 2025), TYSABRI — Total Revenue shows a downward trend with a -5.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption, effective commercial execution, or successful patient retention, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment paradigms.
Detailed definition
This metric represents the total gross sales generated from the commercialization of a specific therapeutic product with...
Peer comparison
Comparable to product-specific revenue lines reported by other large-cap biopharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive biosimilar entry.
biib_segment_tysabri_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $524.20M | $522.80M | $512.80M | $520.80M | $516.20M | $505.50M | $488.40M | $472.80M | $483.10M | $456.30M | $464.70M | $431.30M | $462.20M | $406.10M | $415.40M | $381.50M | $454.60M | $431.80M | $397.50M | $441.50M |
| QoQ Change | — | -0.3% | -1.9% | +1.6% | -0.9% | -2.1% | -3.4% | -3.2% | +2.2% | -5.5% | +1.8% | -7.2% | +7.2% | -12.1% | +2.3% | -8.2% | +19.2% | -5.0% | -7.9% | +11.1% |
| YoY Change | — | — | — | — | -1.5% | -3.3% | -4.8% | -9.2% | -6.4% | -9.7% | -4.9% | -8.8% | -4.3% | -11.0% | -10.6% | -11.5% | -1.6% | +6.3% | -4.3% | +15.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's tysabri — total revenue?
- Biogen (BIIB) reported tysabri — total revenue of $441.50M in Q1 2026.
- How has Biogen's tysabri — total revenue changed year-over-year?
- Biogen's tysabri — total revenue increased by 15.7% year-over-year, from $381.50M to $441.50M.
- What is the long-term trend for Biogen's tysabri — total revenue?
- Over 4 years (2021 to 2025), Biogen's tysabri — total revenue has grown at a -5.2% compound annual growth rate (CAGR), from $2.06B to $1.67B.
- What does tysabri — total revenue mean?
- The total revenue generated from the sales of a specific pharmaceutical product.